The Fish That Did Not Fit in a Bottle
How a supplement built on Arctic blood samples became the most oversold pill in the pharmacy.
In the winter of 1970, two Danish physicians boarded a small plane bound for the northwest coast of Greenland. Hans Olaf Bang and Jorn Dyerberg were not adventurers. They were investigators chasing a rumor buried in old medical records: that the Inuit of Greenland, despite a diet that would horrify any mid-century nutritionist, almost never died of heart attacks.
When they arrived in the settlement of Uummannaq, they found conditions that made research nearly impossible. There were no laboratories, no reliable refrigeration, no easy way to spin blood before it clotted. So Dyerberg improvised. He drew blood from Inuit volunteers on the ice, packed the samples carefully, and flew them back to Denmark for analysis. What he measured there would launch one of the largest health enthusiasms of the twentieth century, and eventually one of its most instructive disappointments.
The Inuit diet was built almost entirely from marine animals: seal, whale, and fatty fish. Vegetables were scarce to nonexistent. By the assumptions of the day, this should have been a recipe for clogged arteries and early death. Instead, the blood samples told a strange story. The Inuit carried unusually high levels of a particular class of fat, long-chain omega-3 fatty acids drawn up through the marine food chain, and unusually low rates of the cardiovascular disease that was killing Danes in droves 1.
Out of that contrast came a hypothesis with the elegance that scientists love and the public adores. Fish fat, Bang and Dyerberg proposed, might protect the human heart. The idea traveled fast, and it hardened into something close to folk wisdom before the evidence had a chance to catch up.
The molecule that seemed too good to fail
To understand why the fish-oil story became so seductive, it helps to understand what omega-3 fatty acids actually are and why the body treats them as precious.
There are three that matter. The first is alpha-linolenic acid, or ALA, which comes from plants such as flaxseed and walnuts. The human body can convert ALA into the more biologically active marine forms, but only inefficiently, often at rates of a few percent. The other two, eicosapentaenoic acid and docosahexaenoic acid, known as EPA and DHA, come mostly from fish and the algae that fish eat. These are the potent forms, the ones Dyerberg found flooding Inuit blood.
Their role in the body is not trivial. DHA is a structural component of cell membranes, and it is especially concentrated in two of the most metabolically demanding tissues we have: the brain and the retina. Roughly sixty percent of the brain, by dry weight, is fat, and DHA is woven directly into the architecture of neurons. From that fact grew a logic that felt almost self-evident. If these fats build the brain and the eye, and if a fish-eating population enjoyed remarkably healthy hearts, then more omega-3 should mean more protection. Eat more, protect more.
That syllogism skipped a step, though nobody wanted to notice at the time. The presence of a molecule in a tissue does not mean that swallowing more of it improves the tissue’s function. But in the 1980s, with the Greenland findings glowing in the background, the caveat was easy to ignore.
The trial that lit the fuse
The first large piece of clinical evidence arrived at the end of the century, and it was genuinely encouraging. In 1999, Italian researchers published the results of the GISSI-Prevenzione trial, which followed more than eleven thousand people who had recently survived a heart attack 2. Some received a daily gram of omega-3, others did not. The group taking fish oil appeared to have fewer sudden cardiac deaths.
This was exactly the kind of result the hypothesis predicted, and it landed in a receptive world. The finding was reported widely, folded into treatment guidelines, and absorbed into the marketing of a fast-growing industry. Fish oil, already popular, became a phenomenon. By the following decade the global market for the supplements would climb into the billions of dollars, and the golden capsule earned a place on bathroom shelves beside the multivitamin.
But a single positive trial, however large, is not a settled science. It is a hypothesis that has survived one test. The GISSI population was specific: heart-attack survivors in Italy in the 1990s, before statins and modern cardiac care became routine. Whether the same benefit would appear in healthier people, in different countries, with better background medicine, was an open question. So researchers did what the scientific method demands. They ran it again, bigger and cleaner.
When the story began to crack
The second wave of evidence was built to a higher standard, and it was far less kind.
At Harvard Medical School, the cardiologist and epidemiologist JoAnn Manson led a study called VITAL, one of the most rigorous tests of the idea ever attempted. Nearly twenty-six thousand generally healthy American adults were randomly assigned to take either a daily fish-oil capsule or a placebo, and then followed for more than five years. Neither the participants nor the researchers knew who was taking what until the code was broken. This is the design that separates real effects from wishful ones.
In 2018, the results appeared in the New England Journal of Medicine 3. For the primary outcome, major cardiovascular events across the whole population, fish oil showed no significant benefit. It did not meaningfully reduce heart attacks and strokes taken together. Nor, in a companion analysis, did it prevent cancer, another hope that had accumulated around the supplement over the years.
The same year brought ASCEND, a British trial that followed more than fifteen thousand people with diabetes, a group at elevated cardiovascular risk and therefore, in theory, a group with more to gain 4. The participants took omega-3 capsules for years. For the group as a whole, the benefit simply did not appear.
The most sweeping verdict came from the Cochrane collaboration, the organization that specializes in pooling many studies into a single, careful synthesis. Led by Lee Hooper at the University of East Anglia, the review gathered data from dozens of trials covering more than a hundred thousand participants 5. The conclusion was blunt in the understated way that systematic reviews tend to be. Increasing long-chain omega-3 through supplements had little or no effect on the risk of dying from heart disease or from any cause. Whatever effect existed was, at best, tiny.
For an industry and a public that had spent decades treating fish oil as heart insurance in a capsule, this was a hard landing. The golden pill had been handed its biggest tests, and it had mostly failed them.
The failure that was not what it looked like
Here is where the story turns, and where it becomes genuinely interesting rather than merely deflating.
Omega-3 itself was never the thing that failed. What failed was the capsule. Read the trials carefully and a pattern emerges that the headlines tended to flatten. The disappointment attached to the supplement, the extracted molecule sealed in a softgel, not to the fatty fish on a dinner plate.
Studies of whole diets, rather than isolated pills, keep pointing the other way. Populations that regularly eat oily fish, roughly two servings a week, show lower rates of heart disease in observational data spanning decades. The signal that first drew Dyerberg north has not vanished. It simply refuses to reproduce when the fish is replaced by an extract.
There are a few reasons this might be so, and none of them requires abandoning the underlying biology. A fillet of salmon or mackerel is not a delivery vehicle for a single molecule. It carries high-quality protein, selenium, iodine, vitamin D, and a whole cluster of compounds that arrive together and may act together. It also tends to displace something worse from the plate. A person eating fish twice a week is often a person eating less processed meat, and diet is a game of substitutions as much as additions. A capsule strips one molecule out of that living context and asks it to perform alone. Often it cannot.
There is also the uncomfortable possibility that the original Greenland picture was never as clean as it became in the retelling. Later scholarship has questioned how reliable the early Inuit mortality statistics really were, given the difficulty of collecting accurate cause-of-death data across a vast and sparsely settled territory 6. The hypothesis may have rested on a foundation shakier than the confidence it inspired. That does not make omega-3 irrelevant. It makes the leap from a striking correlation to a bottled cure look, in hindsight, premature.
The exception that proves the rule
And yet the picture is not simply that supplements do nothing. One trial, published in the same crowded year of 2018, complicates the tidy dismissal.
The study was called REDUCE-IT, and it tested something different from a drugstore softgel 7. Participants were not healthy adults hoping to stay well. They were high-risk patients, most already on statins, many with existing cardiovascular disease or diabetes plus elevated triglycerides. And the intervention was not a modest daily gram of mixed fish oil. It was a prescription drug, a purified and highly concentrated form of EPA, given at roughly four grams a day. That is a pharmaceutical dose, several times what ordinary supplements provide, and a purified molecule rather than the mixed EPA-and-DHA blend found in most capsules.
In that specific, high-risk population, the effect was substantial. The drug cut major cardiovascular events sharply, by around a quarter compared with placebo. This was real, and it was medicine in the fullest sense: a defined compound, a defined dose, a defined patient group, prescribed and monitored.
REDUCE-IT did not vindicate the bathroom-cabinet supplement. If anything, it sharpened the contrast. The trials that failed used lower doses of mixed fish oil in broad populations. The trial that succeeded used a high dose of a purified drug in carefully selected patients. Even then, some researchers have noted questions about the study’s design, including the choice of a mineral-oil placebo that may have nudged the comparison. The benefit appears real, but the conditions attached to it are strict, and none of them describe a healthy person buying capsules on a whim.
What is actually true
So where does this leave the golden capsule, and the eighteen and a half million Americans who reportedly swallow one each morning?
The biology is not a myth. Omega-3 fatty acids really are essential to the structure of the brain, the retina, and the membranes of every cell in the body. DHA and EPA are not marketing inventions. They matter, and a diet chronically deficient in them is a diet with a genuine gap.
What the last two decades of rigorous trials have shown is narrower and more honest than the promise sold on the label. For most healthy people, a general-purpose fish-oil supplement offers little proven protection against heart attack, stroke, cancer, or early death. It will not rescue an otherwise poor diet, and it is not the insurance policy the marketing implied. The absence of a large benefit in these trials is not proof that omega-3 is worthless, only that the pill, in typical doses and typical people, does not deliver what was hoped.
For a specific and smaller group, high-risk cardiac patients under medical supervision, a prescription form at pharmaceutical doses may genuinely help. That is a clinical decision, made with a doctor who knows the patient’s triglycerides and history, not a purchase made in a supplement aisle. The distinction between a drug and a supplement, so easily blurred by identical-looking capsules, turns out to matter enormously.
And for nearly everyone, the most durable lesson is the oldest one, the one buried in Dyerberg’s frozen blood samples all along. The Inuit were never saved by a capsule. They were shaped by a whole way of eating, a pattern of food and environment and habit that no single molecule can reconstruct. When the fish became a pill, something essential was left behind on the plate.
That is the quieter truth beneath the fish-oil story, and it applies far beyond omega-3. Nutrition science keeps trying to isolate the active ingredient, to name the one thing that does the work, and food keeps refusing to cooperate. The next time a golden softgel promises to protect your heart, it is worth remembering the animal it came from, and how little of that animal survives the journey into the bottle.
Sources
- Bang, H. O. and Dyerberg, J., Plasma lipids and lipoproteins in Greenlandic west coast Eskimos, Acta Medica Scandinavica, 1972. — https://pubmed.ncbi.nlm.nih.gov/4514436/
- GISSI-Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction, The Lancet, 1999. — https://pubmed.ncbi.nlm.nih.gov/10465168/
- Manson, J. E. et al., Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL), New England Journal of Medicine, 2019. — https://www.nejm.org/doi/full/10.1056/NEJMoa1811403
- ASCEND Study Collaborative Group, Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus, New England Journal of Medicine, 2018. — https://www.nejm.org/doi/full/10.1056/NEJMoa1804989
- Abdelhamid, A. S., Hooper, L. et al., Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews, 2020. — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/full
- Fodor, J. G. et al., Fishing for the origins of the ‘Eskimos and heart disease’ story, Canadian Journal of Cardiology, 2014. — https://pubmed.ncbi.nlm.nih.gov/24927662/
- Bhatt, D. L. et al., Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT), New England Journal of Medicine, 2019. — https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
Related reading
